Journal of Affective Disorders
Volume 66, Issue 2 , Pages 147-158 , October 2001

A change in the density of [3H]flumazenil, but not [3H]muscimol binding, in Brodmann’s Area 9 from subjects with bipolar disorder

  • Brian Dean

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    • Department of Pathology, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    • Department of Psychiatry, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    • Monash Department of Psychological Medicine, The Alfred, Prahran, Victoria, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61-3-9388-1633; fax: +61-3-9387-5061
    • ,
  • Geoffrey Pavey

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    • ,
  • Mark McLeod

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    • Department of Pathology, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    • ,
  • Kenneth Opeskin

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    • ,
  • Nicholas Keks

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    • Monash Department of Psychological Medicine, The Alfred, Prahran, Victoria, Australia
    • ,
  • David Copolov

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    • Department of Psychiatry, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    • Monash Department of Psychological Medicine, The Alfred, Prahran, Victoria, Australia

Received 1 April 2000 ,Revised 24 July 2000 ,Accepted 4 August 2000.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association; 1994;
  2. Arora RC, Meltzer HY. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural. Transm. Gen. Sect. 1991;85:19–29
  3. Arvanov VL, Wang RY. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-d-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology. 1998;18:197–209
  4. Bennett JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry. 1979;36:927–934
  5. Berrettini WH, Nurnberger-JI J, Hare TA, Simmons AS, Gershon ES, Post RM. Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate. Biol. Psychiat. 1983;18:185–194
  6. Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, et al.  Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 1989;52:1781–1786
  7. Dean B, Opeskin K, Pavey G, Naylor L, Hill C, Keks NA, et al.  [3H]Paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J. Neurochem. 1995;64:1197–1202
  8. Dean B, Hayes W. Decreased frontal cortical serotonin2A receptors in subjects with schizophrenia. Schizophr. Res. 1996;21:133–139
  9. Dean B, Hayes W, Opeskin K, Naylor L, Pavey G, Hill C, et al.  Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 1996;73:169–175
  10. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C, et al.  Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 1999;72:1593–1599
  11. Dean B, Tomaskovic-Crook E, Opeskin K, Keks N, Copolov D. No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem. Int. 1999;34:109–115
  12. Farnbach-Pralong D, Bradbury R, Copolov D, Dean B. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. Eur. J. Pharmacol. 1998;349:R7–R8
  13. Freund G, Ballinger WE. Decrease of benzodiazepine receptors in frontal cortex of alcoholics. Alcohol. 1988;5:275–282
  14. Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M, et al.  CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am. J. Psychiat. 1984;141:1533–1540
  15. Greenamyre JT, Young AB. Synaptic localization of striatal NMDA, quisqualate and kainate receptors. Neurosci. Lett. 1989;101:133–137
  16. Hand KS, Baird VH, Van Paesschen W, Koepp MJ, Revesz T, Thom M, et al.  Central benzodiazepine receptor autoradiography in hippocampal sclerosis. Br. J. Pharmacol. 1997;122:358–364
  17. Herrero MT, Oset-Gasque MJ, Lopez E, Vicente S, Gonzalez MP. Mechanism by which GABA, through its GABA(A) receptor, modulates glutamate release from rat cortical neurons in culture. Neurochem. Int. 1999;34:141–148
  18. Hetmar O, Nielsen M, Braestrup C. Decreased number of benzodiazepine receptors in frontal cortex of rat brain following long-term lithium treatment. J. Neurochem. 1983;41:217–221
  19. Jansen KLR, Faull RLM, Dragunow M, Waldvogel H. Autoradiographic localisation of NMDA, quisqualate and kainic acid receptors in human spinal cord. Neurosci. Lett. 1990;108:53–57
  20. Johnson M, Perry EK, Ince PG, Shaw PJ, Perry RH. Autoradiographic comparison of the distribution of [3H]MK801 and [3H]CNQX in the human cerebellum during development and aging. Brain Res. 1993;615:259–266
  21. Joseph R. Frontal lobe psychopathology: mania, depression, confabulation, catatonia, perseveration, obsessive compulsions, and schizophrenia. Psychiatry. 1999;62:138–172
  22. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993;8:315–336
  23. Keks N, Hill C, Opeskin K, Copolov DL, Dean B. Psychiatric diagnosis after death: the problems of accurate diagnosis. In: The Use of CNS Autopsy Tissue in Psychiatric Research: A Practical Guide. Sydney: J. Gordon and Breach Science Publishers; 1999;p. 19–37
  24. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, et al.  Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Mol. Brain Res. 1995;28:311–318
  25. Kishimoto H, Yamada K, Iseki E, Kosaka K, Okoshi T. Brain imaging of affective disorders and schizophrenia. Psychiat. Clin. Neurosci. 1998;52(Suppl):S212–S214
  26. Kurumaji A, Ishimaru M, Toru M. Alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of chronic schizophrenics. J. Neurochem. 1992;59:829–837
  27. Leake A, Fairbairn AF, McKeith IG, Ferrier IN. Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res. 1991;39:155–165
  28. Miller LG, Greenblatt DJ, Barnhill JG, Shader RI. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acid A receptor function. J. Pharmacol. Exp. Ther. 1988;246:170–176
  29. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori Y, et al.  Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiat. 1986;21:1407–1414
  30. Mohler H, Richards JG. Agonist and antagonist benzodiazepine receptor interaction in vitro. Nature. 1981;294:763–765
  31. Petty F. GABA and mood disorders: a brief review and hypothesis. J. Affect. Disord. 1995;34:275–281
  32. Petty F, Schlesser MA. Plasma GABA in affective illness. A preliminary investigation. J. Affect. Disord. 1981;3:339–343
  33. Piggott MA, Perry EK, Perry RH, Court JA. [3H]MK-801 binding to the NMDA receptor complex, and its modulation in human frontal cortex during development and aging. Brain Res. 1992;588:277–286
  34. Post RM, Frye MA, Denicoff KD, Leverich GS, Kimbrell TA, Dunn RT. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology. 1998;19:206–219
  35. Reichelt R, Hofmann D, Fodisch HJ, Mohler H, Knapp M, Hebebrand J. Ontogeny of the benzodiazepine receptor in human brain: fluorographic, immunochemical, and reversible binding studies. J. Neurochem. 1991;57:1128–1135
  36. Rodbard D. Mathematics and statistics of ligand assays. In: Ligand Assay: Analysis of International Developments on Isotopic and Nonisotopic Immunoassay. New York: Masson; 1981;p. 55–101
  37. Simpson MDC, Slater P, Royston MC, Deakin JFW. Alterations in phencyclidine and sigma binding sites in schizophrenic brains: Effects of disease process and neuroleptic medication. Schizophr. Res. 1991;6:41–48
  38. Soulsby B. Drug Equivalents for Neuroleptics, Antidepressants and Benzodiazepines. 1. Melbourne: Mental Health Research Institute of Victoria; 1999;Computer program
  39. Whitaker PM, Crow TJ, Ferrier IN. Tritiated LSD binding in frontal cortex in schizophrenia. Arch. Gen. Psychiat. 1981;38:278–280
  40. Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol. Psychiat. 1994;35:121–127
  41. Zezula J, Cortes R, Probst A, Palacios JM. Benzodiazepine receptor sites in the human brain: autoradiographic mapping. Neuroscience. 1988;25:771–795
  42. Zhao TJ, Li M, Chiu TH, Rosenberg HC. Decreased benzodiazepine binding with little effect on gamma-aminobutyric acid binding in rat brain after treatment with antisense oligodeoxynucleotide to the gamma-aminobutyric acid A receptor gamma-2 subunit. J. Pharmacol. Exp. Ther. 1998;287:752–759

PII: S0165-0327(00)00294-9

Journal of Affective Disorders
Volume 66, Issue 2 , Pages 147-158 , October 2001

Article Tools

* Image Usage & Resolution